4.4 Article

Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data

期刊

DIABETES TECHNOLOGY & THERAPEUTICS
卷 20, 期 1, 页码 6-16

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2017.0187

关键词

Glycemic variability; Continuous glucose monitoring; Artificial pancreas

资金

  1. Dexcom
  2. Medtronic
  3. Tandem
  4. Insulet
  5. Bigfoot Medical

向作者/读者索取更多资源

Background: High levels of glycemic variability are still observed in most patients with diabetes with severe insulin deficiency. Glycemic variability may be an important risk factor for acute and chronic complications. Despite its clinical importance, there is no consensus on the optimum method for characterizing glycemic variability. Method: We developed a simple new metric, the glycemic variability percentage (GVP), to assess glycemic variability by analyzing the length of the continuous glucose monitoring (CGM) temporal trace normalized to the duration under evaluation. The GVP is similar to other recently proposed glycemic variability metrics, the distance traveled, and the mean absolute glucose (MAG) change. We compared results from distance traveled, MAG, GVP, standard deviation (SD), and coefficient of variation (CV) applied to simulated CGM traces accentuating the difference between amplitude and frequency of oscillations. The GVP metric was also applied to data from clinical studies for the Dexcom G4 Platinum CGM in subjects without diabetes, with type 2 diabetes, and with type 1 diabetes (adults, adolescents, and children). Results: In contrast to other metrics, such as CV and SD, the distance traveled, MAG, and GVP all captured both the amplitude and frequency of glucose oscillations. The GVP metric was also able to differentiate between diabetic and nondiabetic subjects and between subjects with diabetes with low, moderate, and high glycemic variability based on interquartile analysis. Conclusion: A new metric for the assessment of glycemic variability has been shown to capture glycemic variability due to fluctuations in both the amplitude and frequency of glucose given by CGM data.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study

Gregory P. Forlenza, Tim Vigers, Cari Berget, Laurel H. Messer, Rayhan A. Lal, Marina Basina, David M. Maahs, Korey Hood, Bruce Buckingham, Darrell M. Wilson, R. Paul Wadwa, Kimberly A. Driscoll, Laura Pyle

Summary: This study developed and validated prognostic models for successful 12-month use of the first commercial HCL system based on baseline and 1- or 3-month data. Factors in the final model included baseline HbA1c, sex, ethnicity, 1- or 3-month Auto Mode use, Boluses per Day, and time in range. The prognostic models had very good predictive ability and may be useful for targeted interventions to promote success with new technologies.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial

Laya Ekhlaspour, Marissa Town, Dan Raghinaru, John W. Lum, Sue A. Brown, Bruce A. Buckingham

Summary: Using a closed-loop system can significantly improve time in range for patients with type 1 diabetes. Patients with different HbA1c levels showed improvements in blood sugar control through automated insulin adjustments, regardless of whether they had high or low blood sugar levels.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Correction Endocrinology & Metabolism

Continuous Glucose Monitoring: An Endocrine Society Clinical Practice Guideline (vol 106, e2460, 2021)

D. C. Klonoff, B. Buckingham, J. S. Christiansen, V. M. Montori, W. Tamborlane, R. A. Vigersky, H. Wolpert

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Endocrinology & Metabolism

Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial

Gregory P. Forlenza, Laya Ekhlaspour, Linda A. DiMeglio, Larry A. Fox, Henry Rodriguez, Dorothy I. Shulman, Kevin B. Kaiserman, David R. Liljenquist, John Shin, Scott W. Lee, Bruce A. Buckingham

Summary: The study found that using MiniMed (TM) 670G system in Auto Mode improved glycemic outcomes in young children with T1D compared to Manual Mode, including A1C levels, blood glucose control, and minimizing severe hypoglycemia. The results were similar to those seen in older children, adolescents, and adults with T1D using the system for the same duration of time.

PEDIATRIC DIABETES (2022)

Article Biochemical Research Methods

Automation of a multiplex agglutination-PCR (ADAP) type 1 diabetes (T1D) assay for the rapid analysis of islet autoantibodies

Felipe de Jesus Cortez, David Gebhart, Devangkumar Tandel, Peter Robinson, David Seftel, Darrell M. Wilson, David M. Maahs, Bruce A. Buckingham, Kevin W. P. Miller, Cheng-ting Tsai

Summary: This study presents an automated high-throughput multiplex islet autoantibody assay that utilizes agglutination-PCR chemistry for antibody detection. The automated system is capable of processing a large number of samples in a short time, requiring only a small volume of serum samples, making it suitable for large-scale analysis of islet autoantibodies.

SLAS TECHNOLOGY (2022)

Letter Endocrinology & Metabolism

Smartwatch gesture-based meal reminders improve glycaemic control

John P. Corbett, Liana Hsu, Sue A. Brown, Laura Kollar, Katelijn Vleugels, Bruce Buckingham, Marc D. Breton, Rayhan A. Lal

DIABETES OBESITY & METABOLISM (2022)

Article Endocrinology & Metabolism

Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4

Jordan E. Pinsker, Eyal Dassau, Sunil Deshpande, Dan Raghinaru, Bruce A. Buckingham, Yogish C. Kudva, Lori M. Laffel, Carol J. Levy, Mei Mei Church, Hannah Desrochers, Laya Ekhlaspour, Ravinder Jeet Kaur, Camilla Levister, Dawei Shi, John W. Lum, Craig Kollman, Francis J. Doyle, iDCL Trial Res Grp

Summary: The automated adaptation of insulin delivery settings did not significantly improve time-in-range in this well-controlled population of diabetes patients. Additional studies and further refinement of the adaptation system are needed, especially in populations with different degrees of baseline glycemic control, who may benefit more from adaptation.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial

Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham

Summary: This trial evaluated the safety and performance of a new extended-wear infusion set when used for 7 days by adults with type 1 diabetes. The results showed that the extended-wear infusion set was safe and rated with high satisfaction by patients, without adversely affecting glycemic control.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Article Endocrinology & Metabolism

Pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready-to-use, room temperature, liquid stable glucagon administered via an autoinjector pen to youth with type 1 diabetes

Bruce Buckingham, Jennifer Sherr, Steven J. Prestrelski, Valentina Conoscenti

Summary: The study aims to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of a ready-to-use glucagon formulation in youth with type 1 diabetes. The results show that the formulation effectively reverses low blood glucose concentrations in youth with type 1 diabetes.

PEDIATRIC DIABETES (2022)

Article Endocrinology & Metabolism

Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial

Laya Ekhlaspour, Dan Raghinaru, Gregory P. Forlenza, Elvira Isganaitis, Yogish C. Kudva, David W. Lam, Camilla Levister, Grenye O'Malley, Mei Mei Church, John W. Lum, Bruce Buckingham, Sue A. Brown

Summary: The study investigated the potential benefits of automated insulin delivery among individuals with type 1 diabetes, regardless of their baseline device use or CGM status. The results showed that the closed-loop control system significantly improved glycemic outcomes in both insulin pump and MDI users with or without CGM.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2023)

Article Endocrinology & Metabolism

Improving the Patient Experience With Longer Wear Infusion Sets Symposium Report

Kevin T. Nguyen, Nicole Y. Xu, Bruce A. Buckingham, Sarnath Chattaraj, Ohad Cohen, Lutz Heinemann, John Pickup, Jannet Svensson, Robert A. Vigersky, Jenise C. Wong, Ralph Ziegler

Summary: Continuous subcutaneous insulin infusion (CSII) therapy is gaining popularity due to its convenient insulin delivery, precise dosing, easy adjustments, and integration with continuous glucose monitors. However, technology for insulin infusion sets (IISs) has not kept pace with advancements in insulin pump hardware and software, posing challenges to CSII. To address these barriers and showcase advancements in longer wear IISs, a symposium was held, featuring experts in the field and covering topics such as insulin pump therapy advancements, efficacy of longer wear infusion sets, and innovation in reducing waste.

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY (2022)

Article Endocrinology & Metabolism

Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial

Jennifer L. Sherr, Bruce W. Bode, Gregory P. Forlenza, Lori M. Laffel, Melissa J. Schoelwer, Bruce A. Buckingham, Amy B. Criego, Daniel J. DeSalvo, Sarah A. MacLeish, David W. Hansen, Trang T. Ly

Summary: This study evaluated the use of the Omnipod 5 Automated Insulin Delivery System in very young children with type 1 diabetes. The results showed that the system was safe to use and led to improved glycemic control and reduced hypoglycemia in the participants.

DIABETES CARE (2022)

Review Endocrinology & Metabolism

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Moshe Phillip, Revital Nimri, Richard M. Bergenstal, Katharine Barnard-Kelly, Thomas Danne, Roman Hovorka, Boris P. Kovatchev, Laurel H. Messer, Christopher G. Parkin, Louise Ambler-Osborn, Stephanie A. Amiel, Lia Bally, Roy W. Beck, Sarah Biester, Torben Biester, Julia E. Blanchette, Emanuele Bosi, Charlotte K. Boughton, Marc D. Breton, Sue A. Brown, Bruce A. Buckingham, Albert Cai, Anders L. Carlson, Jessica R. Castle, Pratik Choudhary, Kelly L. Close, Claudio Cobelli, Amy B. Criego, Elizabeth Davis, Carine de Beaufort, Martin de Bock, Daniel J. DeSalvo, J. Hans DeVries, Klemen Dovc, Francis J. Doyle, Laya Ekhlaspour, Naama Fisch Shvalb, Gregory P. Forlenza, Geraldine Gallen, Satish K. Garg, Dana C. Gershenoff, Linda A. Gonder-Frederick, Ahmad Haidar, Sara Hartnell, Lutz Heinemann, Simon Heller, Irl B. Hirsch, Korey K. Hood, Diana Isaacs, David C. Klonoff, Olga Kordonouri, Aaron Kowalski, Lori Laffel, Julia Lawton, Rayhan A. Lal, Lalantha Leelarathna, David M. Maahs, Helen R. Murphy, Kirsten Norgaard, David O'Neal, Sean Oser, Tamara Oser, Eric Renard, Michael C. Riddell, David Rodbard, Steven J. Russell, Desmond A. Schatz, Viral N. Shah, Jennifer L. Sherr, Gregg D. Simonson, R. Paul Wadwa, Candice Ward, Stuart A. Weinzimer, Emma G. Wilmot, Tadej Battelino

Summary: The global prevalence of diabetes continues to be a challenge and the advances in automated insulin delivery (AID) technologies have shown to be safe and effective in helping patients achieve their glycemic goals. However, there is a lack of guidance for clinicians on using AID systems in clinical settings.

ENDOCRINE REVIEWS (2023)

Article Endocrinology & Metabolism

Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial

Satish K. Garg, George Grunberger, Ruth Weinstock, Margaret L. Lawson, Irl B. Hirsch, Linda A. DiMeglio, Rodica Pop-Busui, Athena Philis-Tsimikas, Mark Kipnes, David R. Liljenquist, Ronald L. Brazg, Yogish C. Kudva, Bruce A. Buckingham, Janet B. McGill, Anders L. Carlson, Amy B. Criego, Mark P. Christiansen, Kevin B. Kaiserman, Kurt J. Griffin, Greg P. Forlenza, Bruce W. Bode, Robert H. Slover, Ashleigh Keiter, Chenxiao Ling, Briggitte Marinos, Toni L. Cordero, John Shin, Scott W. Lee, Andrew S. Rhinehart, Robert A. Vigersky

Summary: This study evaluates the safety and effectiveness of MiniMed 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for individuals with type 1 diabetes (T1D). The results show that HCL intervention significantly improves A1C levels and reduces the percentage of time spent with blood glucose below 70 mg/dL, with good safety profile.

DIABETES TECHNOLOGY & THERAPEUTICS (2023)

Review Endocrinology & Metabolism

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

Tadej Battelino, Charles M. Alexander, Stephanie A. Amiel, Guillermo Arreaza-Rubin, Roy W. Beck, Richard M. Bergenstal, Bruce A. Buckingham, James Carroll, Antonio Ceriello, Elaine Chow, Pratik Choudhary, Kelly Close, Thomas Danne, Sanjoy Dutta, Robert Gabbay, Satish Garg, Julie Heverly, Irl B. Hirsch, Tina Kader, Julia Kenney, Boris Kovatchev, Lori Laffel, David Maahs, Chantal Mathieu, Didac Mauricio, Revital Nimri, Rimei Nishimura, Mauro Scharf, Stefano Del Prato, Eric Renard, Julio Rosenstock, Banshi Saboo, Kohjiro Ueki, Guillermo E. Umpierrez, Stuart A. Weinzimer, Moshe Phillip

Summary: Randomised controlled trials and other prospective clinical studies have traditionally used HbA1c as a measure of average blood glucose levels, but with the increasing use of continuous glucose monitoring (CGM), CGM-derived metrics are being considered for use in these studies. This consensus statement recommends the use of CGM data in clinical studies to provide additional clinical information beyond HbA1c. Standardizing the collection and reporting of CGM data in clinical trials can enhance the interpretability of the data and inform therapeutic decisions related to hypoglycaemia, postprandial hyperglycaemia, and glucose variability.

LANCET DIABETES & ENDOCRINOLOGY (2023)

暂无数据